Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

被引：0
|
作者：
Hirohito Shimizu
Hisanori Kobayashi
Masayoshi Kanbori
Yutaka Ishii
机构：
[1] Janssen Pharmaceutical K.K,Medical Affairs Division, Immunology Department
[2] R&D Janssen Pharmaceutical K.K.,Clinical Science Division, External Collaboration and Portfolio Management Department
[3] Janssen Pharmaceutical K.K.,Japan Safety & Surveillance Division, Research & Development Division
来源：
Rheumatology and Therapy | 2020年 / 7卷
关键词：
Dose escalation; Golimumab; Post-marketing surveillance; Real-world evidence; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：311 / 325
页数：14
相关论文
共 50 条
  • [21] Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
    Koike, Takao
    Harigai, Masayoshi
    Ishiguro, Naoki
    Inokuma, Shigeko
    Ryu, Junnosuke
    Takei, Syuji
    Takeuchi, Tsutomu
    Tanaka, Y.
    Watanabe, Masahiko
    Yamanaka, Hisashi
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S598 - S598
  • [22] Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
    Tamura, Naoto
    Kuwana, Masataka
    Atsumi, Tatsuya
    Takei, Syuji
    Harigai, Masayoshi
    Fujii, Takao
    Matsuno, Hiroaki
    Mimori, Tsuneyo
    Momohara, Shigeki
    Yamamoto, Kazuhiko
    Takasaki, Yoshinari
    Nomura, Kazuto
    Endo, Yutaka
    Hirose, Tomohiro
    Morishima, Yosuke
    Sugiyama, Naonobu
    Yoshii, Noritoshi
    Takagi, Michiaki
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [23] POST-MARKETING SAFETY SURVEILLANCE OF TOFACITINIB OVER 9 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
    Burmester, G. R.
    Coates, L.
    Cohen, S. B.
    Tanaka, Y.
    Vranic, I.
    Nagy, E.
    Chen, A. S.
    Lazariciu, I.
    Kwok, K.
    Fallon, L.
    Kinch, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 347 - 348
  • [24] Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Burmester, Gerd R.
    Coates, Laura C.
    Cohen, Stanley B.
    Tanaka, Yoshiya
    Vranic, Ivana
    Nagy, Edward
    Lazariciu, Irina
    Chen, All-shine
    Kwok, Kenneth
    Fallon, Lara
    Kinch, Cassandra
    RHEUMATOLOGY AND THERAPY, 2023, 10 (05) : 1255 - 1276
  • [25] Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Gerd R. Burmester
    Laura C. Coates
    Stanley B. Cohen
    Yoshiya Tanaka
    Ivana Vranic
    Edward Nagy
    Irina Lazariciu
    All-shine Chen
    Kenneth Kwok
    Lara Fallon
    Cassandra Kinch
    Rheumatology and Therapy, 2023, 10 : 1255 - 1276
  • [26] Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
    Nakamura, Shiro
    Asano, Teita
    Tsuchiya, Hiroaki
    Sugimoto, Kanami
    Imai, Yuya
    Yokoyama, Seiji
    Suzuki, Yasuo
    INTESTINAL RESEARCH, 2022, 20 (03) : 329 - +
  • [27] Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study
    Ju, Ji Hyeon
    Sung, Yoon-Kyoung
    Jo, Joo-young
    Jeon, Ja-Young
    Yoo, Hyun-Jeong
    Lee, Eun Bong
    MODERN RHEUMATOLOGY, 2023, 33 (06) : 1087 - 1096
  • [28] The influence of comorbid conditions on the safety profile of infliximab treatment in Japanese patients with rheumatoid arthritis: The post-marketing surveillance trial.
    Yano, Toshiro
    Togo, Masanori
    Nogami, Yoshihide
    Takeuchi, Tsutomu
    Koike, Takao
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S426 - S426
  • [29] Safety and tolerability of agalsidase beta infusions shorter than 90 min in patients with Fabry disease: post-hoc analysis of a Japanese post-marketing study
    Lee, Chae Sung
    Tsurumi, Mina
    Eto, Yoshikatsu
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [30] Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
    Gerd R. Burmester
    Laura C. Coates
    Stanley B. Cohen
    Yoshiya Tanaka
    Ivana Vranic
    Edward Nagy
    Irina Lazariciu
    All-shine Chen
    Kenneth Kwok
    Lara Fallon
    Cassandra Kinch
    Rheumatology and Therapy, 2024, 11 (1) : 221 - 222
12345